Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects

Next Previous
Search
Trial Profile

A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir (Primary) ; Rilpivirine (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LATTE
  • Sponsors ViiV Healthcare

Most Recent Events

  • 11 Jul 2019 Status changed from active, no longer recruiting to completed.
  • 05 Mar 2018 Planned End Date changed from 1 Dec 2020 to 20 Nov 2018.
  • 16 Feb 2017 Results assessing long term safety and efficacy of CAB and RPV, presented at the 24th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top